Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry|February 7, 2006
Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonistsWilliam F Kiesman, Jin Zhao, Patrick R Conlon, et al.Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonistsGang Yao, Serajul Haque, Li Sha, et al.Journal of Medicinal Chemistry|November 28, 2006
Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonistsChi B Vu, William F Kiesman, Patrick R Conlon, et al.Journal of Medicinal Chemistry|November 28, 2006
Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonistsWilliam F Kiesman, Jin Zhao, Patrick R Conlon, et al.Molecular Cancer Therapeutics|March 16, 2021
The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2bNatalya D Bodyak, Rebecca Mosher, Aleksandr V Yurkovetskiy, et al.Molecular Cancer Therapeutics|March 16, 2021
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander EffectAleksandr V Yurkovetskiy, Natalya D Bodyak, Mao Yin, et al.Molecular Cancer Therapeutics|June 9, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of CancerDorin Toader, Shawn P Fessler, Scott D Collins, et al.Pageof 1